Kura Oncology (NASDAQ:KURA) Sets New 1-Year Low – Time to Sell?

Shares of Kura Oncology, Inc. (NASDAQ:KURA) reached a new 52-week low during trading on Tuesday . The company traded as low as $8.34 and last traded at $8.56, with a volume of 96391 shares trading hands. The stock had previously closed at $8.51.

Wall Street Analysts Forecast Growth

A number of equities analysts recently weighed in on the stock. UBS Group assumed coverage on shares of Kura Oncology in a research report on Thursday, October 24th. They set a “buy” rating and a $27.00 price objective for the company. Stifel Nicolaus cut shares of Kura Oncology from a “buy” rating to a “hold” rating and decreased their price target for the company from $26.00 to $19.00 in a research report on Monday, October 14th. StockNews.com cut shares of Kura Oncology from a “hold” rating to a “sell” rating in a research report on Wednesday, November 20th. HC Wainwright raised their price target on shares of Kura Oncology from $32.00 to $37.00 and gave the company a “buy” rating in a research report on Thursday, November 21st. Finally, Jefferies Financial Group decreased their price target on shares of Kura Oncology from $32.00 to $28.00 and set a “buy” rating for the company in a research report on Thursday, November 21st. One analyst has rated the stock with a sell rating, one has assigned a hold rating, eight have given a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $29.86.

Kura Oncology Trading Down 1.6 %

The firm has a market cap of $650.88 million, a PE ratio of -3.55 and a beta of 0.81. The company’s fifty day moving average price is $12.29 and its two-hundred day moving average price is $17.17. The company has a quick ratio of 11.47, a current ratio of 11.47 and a debt-to-equity ratio of 0.02.

Institutional Trading of Kura Oncology

A number of institutional investors have recently added to or reduced their stakes in the stock. JPMorgan Chase & Co. boosted its holdings in Kura Oncology by 0.8% during the third quarter. JPMorgan Chase & Co. now owns 409,241 shares of the company’s stock worth $7,997,000 after buying an additional 3,092 shares in the last quarter. Franklin Resources Inc. boosted its holdings in Kura Oncology by 1.5% during the third quarter. Franklin Resources Inc. now owns 1,588,401 shares of the company’s stock worth $28,687,000 after buying an additional 23,113 shares in the last quarter. Geode Capital Management LLC lifted its holdings in shares of Kura Oncology by 2.4% in the third quarter. Geode Capital Management LLC now owns 1,780,509 shares of the company’s stock valued at $34,798,000 after purchasing an additional 41,535 shares in the last quarter. Barclays PLC raised its position in shares of Kura Oncology by 104.5% in the third quarter. Barclays PLC now owns 165,484 shares of the company’s stock valued at $3,234,000 after buying an additional 84,563 shares during the last quarter. Finally, Jane Street Group LLC raised its position in shares of Kura Oncology by 36.7% in the third quarter. Jane Street Group LLC now owns 126,085 shares of the company’s stock valued at $2,464,000 after buying an additional 33,848 shares during the last quarter.

About Kura Oncology

Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company’s pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors.